Market Outlook for Biosimilars - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Market Outlook for Biosimilars
The author reviews the major biopharmaceutical markets' activity and predicts how the markets may evolve.


Pharmaceutical Technology


References

1. P. Narang, Datamonitor Biosimilars Series 2008: Forecast Analysis (DMHC2477, Datamonitor, London, June 2009).

2. IMS Health, MIDAS sales data (Norwalk, CT, March 2009).

3. S.W. Schondelmeyer, L. Purvis, and D.J. Gross, Rx Watchdog Report: Trends in Manufacturer Prices of Specialty Prescription Drugs Used by Medicare Beneficiaries 2004 to 2007 (AARP Public Policy Institute, Washington, DC, 2008), http://assets.aarp.org/rgcenter/health/2008_15_specialty_q407.pdf, accessed March 2009.

4. S. Sutter, "US House Panel Adopts 12-Year Exclusivity," Scrip (3457), 1 (2009).

5. I. Schofield, "EC Defends Biosimilar Safety," Scrip (3358), 1 (2008).

6. I. Schofield, "Biosimilars Struggling with the Market," Scrip (3359–3360), 23 (2008).

7. Business Monitor International, "First Biosimilar Submitted for Approval," in BMI Industry Insights—Pharma and Healthcare, Asia (London, November 27, 2008).

8. W. Marth, remarks at Bank of America Securities Health Care Conference (Las Vegas, NV, 2008).

9. E.F. Licking, "Merck's Ambitious Plans for Follow-On Biologics," BioPharma Today (2008), http://www.biopharmatoday.com/2008/12/mercks-ambitious-plansfor-follow-on-biologics.html, accessed August 18, 2009.

10. A. Witty, remarks at Goldman Sachs CEOs Unscripted Healthcare Conference (New York, 2009).

11. T. Staton, "J&J Says 'Not Now' on Biosimilars" FiercePharma April 8, 2009, http://www.fiercepharma.com/story/j-j-says-not-now-biosimilars/2009-04-08, accessed August 20, 2009.

12. I. Schofield, "Biosimilars Regulation Finds Its Feet," Scrip (100), 63–64 (2008).

13. N. Faigen, "No End in Sight for Biosimilar Data Exclusivity Debate," Scrip Online (November 27, 2008), http://www.scripnews.com/policyregulation/No-end-in-sight-for-biosimilar-data-exclusivity-debate-9064?autnID=/contentstore/scripnews/codex/7f1db720-bc67-11dd-9174-39d0f0d8ae6e.xml, accessed August 20, 2009.

14. FDA, "US FDA Considerations: Discussion by National Regulatory Authorities with World Health Organization (WHO) on Possible International Non-Proprietary Name (INN) Policies for Biosimilars," (Center for Drug Evaluation and Research, Silver Spring, MD, 2006), http://www.fda.gov/cder/news/biosimilars.htm, accessed March 26, 2009.

15. S. King, "Big Pharma Turns to Biologics for Growth" (DMHC2190, Datamonitor, London, May 2006).

16. "Zenotech Builds Pipeline of 'Generic' Monoclonals," Scrip (3237), 10 (2007).

17. T. Ignjatovic, Biosimilars Series: Strategic Issues—Potential Remains Uncertain (DMHC2337, Datamonitor, London, October 2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here